| A-01 Registration at the conference venue Tuesday 14:00-18:00 |
| A-02 Welcome reception Tuesday 18:30-21:30 |
| B-01 Registration at the conference venue Wednesday 08:00-08:45 |
| B-02 Welcome and Introduction Wednesday 08:45-09:00 |
| B-03 Thierry Buclin Meeting clinicians' and patients' needs in the practice of therapeutic monitoring Wednesday 09:00-09:20 |
| B-04 Catherine Sherwin Model-based Dose Individualization Approaches Using Biomarkers Wednesday 09:20-09:50 |
| B-05 Ron Keizer Experiences in applied clinical pharmacometrics: challenges, recommendations, and research opportunities Wednesday 09:50-10:10 |
| B-06 Coffee break, poster and software session I: posters in Group I (with poster numbers starting with I-) are accompanied by their presenter Wednesday 10:10-11:40 |
| B-07 Maddalena Centanni A pharmacometric framework for dose individualisation of sunitinib in GIST Wednesday 11:40-12:00 |
| B-08 Chloe Pasin Use of mathematical modeling for optimizing and adapting immunotherapy protocols in HIV-infected patients Wednesday 12:00-12:20 |
| B-09 Mouna Akacha Background on estimands and why are they important? Wednesday 12:20-12:35 |
| B-10 Michael Looby PMX perspective on Estimands Wednesday 12:35-12:50 |
| B-11 Discussion on estimands Wednesday 12:50-13:00 |
| B-12 Lunch Wednesday 13:00-14:30 |
| B-13 Camille Vong Power assessment for hierarchical combination endpoints using joint modelling of repeated time-to-event and time-to-event models versus Finkelstein-Schoenfeld method Wednesday 14:30-14:50 |
| B-14 Yixuan Zou A novel score test-based method for efficient covariate selection in population pharmacokinetic analysis Wednesday 14:50-15:10 |
| B-15 Qing Xi Ooi Evaluation of assumptions underpinning pharmacometric models Wednesday 15:10-15:30 |
| B-16 Mats Karlsson Extensive and automatic assumption assessment of pharmacometric models Wednesday 15:30-15:50 |
| B-17 Tea break, poster and software session II: posters in Group II (with poster numbers starting with II-) are accompanied by their presenter Wednesday 15:50-17:20 |
| B-18 Oskar Alskär An integrated glucose homeostasis model of glucose, insulin, C-peptide, GLP-1, GIP and glucagon in healthy subjects and patients with Type 2 diabetes Wednesday 17:20-17:40 |
| B-19 Daniel Hill-McManus Application of a linked pharmacometric/pharmacoeconomic model to assess the impact of non-adherence: Application to the treatment of gout Wednesday 17:40-18:00 |
| C-01 Simon Buatois A pharmacometric extension of MCP-MOD in dose finding studies Thursday 08:30-08:50 |
| C-02 Benjamin Guiastrennec New dosing recommendations for anti-tuberculosis therapy in Indian children Thursday 08:50-09:10 |
| C-03 Jurgen Langenhorst Cause-specific hazard models with markovian elements to quantify the fludarabine exposure-response relationship: from learning to confirming in allogeneic hematopoietic cell transplantation Thursday 09:10-09:30 |
| C-04 Gustaf Wellhagen A bounded integer model for rating and composite scale data Thursday 09:30-09:50 |
| C-05 Presentation of Lewis Sheiner student session awards Thursday 09:50-09:55 |
| C-06 Coffee break, poster and software session III: posters in Group III (with poster numbers starting with III-) are accompanied by their presenter Thursday 09:55-11:30 |
| C-07 Phyllis Chan Assessment of a model to correlate early tumor size response to overall survival in relapsed or refractory diffuse large B cell lymphoma patients Thursday 11:30-11:50 |
| C-08 Rui Zhu Exposure-response (E-R)-based product-profile (PP)-driven clinical utility index (CUI) to support phase III dose selection in oncology Thursday 11:50-12:10 |
| C-09 Zinnia Parra-Guillen A quantitative modelling framework to inform dose selection of Xentuzumab, a dual insulin-like growth factor-I/II neutralizing antibody in cancer patients Thursday 12:10-12:30 |
| C-10 Announcement for ACoP9 (2018) Thursday 12:30-12:35 |
| C-11 Lunch Thursday 12:35-14:10 |
| C-12 Scott Pruitt Clinical Overview of Immunotherapy in Oncology Thursday 14:10-14:40 |
| C-13 Benjamin Ribba Drug response variability and optimal dosing in immuno-oncology Thursday 14:40-15:10 |
| C-14 Tea break, poster and software session IV: posters in Group IV (with poster numbers starting with IV-) are accompanied by their presenter Thursday 15:10-16:40 |
| C-15 Rukmini Kumar Predicting response and identifying responders to combination cancer immunotherapy in melanoma using Quantitative Systems Pharmacology (QSP) models Thursday 16:40-17:00 |
| C-16 Hanna Silber Baumann PKPD analysis of soluble CD25 to characterize the concentration-effect relationship observed following the administration of Cergutuzumab Amunaleukin, a targeted immunocytokine for cancer immunotherapy Thursday 17:00-17:20 |
| C-17 Announcement for WCoP 2020 Thursday 17:20-17:25 |
| C-18 Social event Thursday 18:30-01:30 |
| D-01 David Ternant Population and Bayesian kinetic modelling of necrosis biomarkers to assess the effect of conditioning therapies on infarct size Friday 09:15-09:35 |
| D-02 João Abrantes Integrated modelling of factor VIII activity kinetics, occurrence of bleeds and individual characteristics in haemophilia A patients using a full random effects modelling (FREM) approach Friday 09:35-09:55 |
| D-03 Elin Boger A partial differential equation approach to inhalation PBPK modelling Friday 09:55-10:15 |
| D-04 Chihiro Hasegawa Simplification of multi-scale systems models for data-driven analyses: what has progressed in these 5 years? Friday 10:15-10:35 |
| D-05 Preview of PAGE2019 Friday 10:35-10:40 |
| D-06 Coffee break Friday 10:40-11:20 |
| D-07 DDMoRe Model Repository challenge – prize ceremony Friday 11:20-11:30 |
| D-08 Sulav Duwal A multiscale systems pharmacology framework to predict drug-class specific prophylactic efficacy of antivirals against HIV Friday 11:30-11:50 |
| D-09 Vincent Madelain Ebola viral dynamics in nonhuman primates: insights into virus immuno-pathogenesis and antiviral strategies Friday 11:50-12:10 |
| D-10 Closing remarks Friday 12:10-12:20 |
| D-11 Audience input for potential PAGE2018 topics Friday 12:20-12:35 |
